volume 24, issue 2, P439-459 2010
DOI: 10.1016/j.idc.2010.01.002
View full text
|
|
Share

Abstract: Recent shifts in the epidemiology of invasive fungal infections (IFIs) among transplant and oncology populations have led to new recommendations on treatment; however, they have also brought new controversies. New pharmacologic therapies are being studied and guidelines for management of several IFIs have been changed accordingly. More information is being discovered about unique genetic factors that put some transplant recipients at greater risk than others for fungal infection. The role of immunomodulation c…

expand abstract